Reading CPRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CPRX free→Reading CPRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CPRX free→QuarterlyIQ Insights · CPRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events On May 7, 2026, the Company issued a press release announcing that it and its licensor, SERB S.A. (“ SERB ”) have entered into a settlement agreement (“ Settlement Agreement ”) with Hetero USA, Inc. (“ Hetero ”). This Settlement Agreement resolves the patent litigation brought by the Company and SERB in response to Hetero’s Abbreviated New Drug Application (“ ANDA ”) seeking approval to market a generic version of FIRDAPSE ® (amifampridine) 10 mg tablets prior to expiration of th…
Entry into a Material Definitive Agreement On May 6, 2026, Catalyst Pharmaceuticals, Inc. (“ Catalyst ” or the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Angelini Pharma S.p.A., an Italian Società per azioni (“ Angelini Pharma ” or “ Parent ”), and Angelini Cielo Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”), with the Company s…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.